Drugs / Hepatitis B immunoglobulins
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05293158 | Nov 2024 → Jun 2026 | chronic hepatitis B virus infection, hepatocellular carcinoma | Medical University of Graz | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hepatitis B immunoglobulins | “Hepatitis B immunoglobulins (HBIG) can directly bind and neutralize extracellular HBsAg/SVPs” NCT05293158 ↗ |
| Known as | HBIG | “Hepatitis B immunoglobulins (HBIG) can directly bind and neutralize extracellular HBsAg/SVPs” NCT05293158 ↗ |
| Action | Inhibit | “Hepatitis B immunoglobulins (HBIG) can directly bind and neutralize extracellular HBsAg/SVPs” NCT05293158 ↗ |
| Modality | Protein / enzyme biologic | “Hepatitis B immunoglobulins” NCT05293158 ↗ |
| Route | Intravenous | “Application of i.v. (intravenously) HBIGs” NCT05293158 ↗ |